Memantine and catatonia: a case report and literature review - PubMed

Review

Memantine and catatonia: a case report and literature review

Demian F Obregon et al. J Psychiatr Pract. 2011 Jul.

Abstract

Catatonia is a movement disorder with various possible etiologies. The majority of cases are associated with an underlying mood or psychotic disorder, while others are caused by medical conditions. Currently, benzodiazepines are the first-line psychopharmacologic agents in the treatment of catatonia. However, several cases have been reported in which treatment with memantine proved to be effective. We present the case of a 92-year-old female with major depressive disorder and associated catatonic symptoms. In this case, the patient's symptoms remitted quickly after the initiation of memantine. We review the possible causes of catatonia and pharmacologic treatments for the condition and highlight the possible benefits of N-methylD-aspartic acid receptor antagonists such as memantine in the treatment of catatonia.

Similar articles

• Catatonic schizophrenia and the use of memantine.

  Carpenter SS, Hatchett AD, Fuller MA. Carpenter SS, et al. Ann Pharmacother. 2006 Feb;40(2):344-6. doi: 10.1345/aph.1G297. Epub 2005 Dec 27. Ann Pharmacother. 2006. PMID: 16380435

• [Use of aripiprazole in the treatment of catatonia].

  Vörös V, Tényi T. Vörös V, et al. Neuropsychopharmacol Hung. 2010 Jun;12(2):373-6. Neuropsychopharmacol Hung. 2010. PMID: 20606247 Hungarian.

• Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy.

  Utumi Y, Iseki E, Arai H. Utumi Y, et al. Psychogeriatrics. 2013 Dec;13(4):254-9. doi: 10.1111/psyg.12027. Epub 2013 Oct 24. Psychogeriatrics. 2013. PMID: 24164753

• [Efficacy of memantine in the treatment of Alzheimer's disease].

  Molinuevo Guix JL, Lladó Plarrumaní A. Molinuevo Guix JL, et al. Neurologia. 2005 Dec;20(10):686-91. Neurologia. 2005. PMID: 16317590 Review. Spanish.

• [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].

  Frölich L, Schmitt B, Calabrese P, Diener H, Förstl H, Gertz HJ, Hallauer JF, Hampel H, Ihl R, Rieke K, Riepe M, Supprian T. Frölich L, et al. Dtsch Med Wochenschr. 2005 Feb 25;130(8):408-12. doi: 10.1055/s-2005-863066. Dtsch Med Wochenschr. 2005. PMID: 15717252 Review. German. No abstract available.

Cited by

• A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life.

  Strzelecki D, Tabaszewska A, Barszcz Z, Józefowicz O, Kropiwnicki P, Rabe-Jabłońska J. Strzelecki D, et al. Psychiatry Investig. 2013 Dec;10(4):421-4. doi: 10.4306/pi.2013.10.4.421. Epub 2013 Dec 16. Psychiatry Investig. 2013. PMID: 24474993 Free PMC article.

• Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia.

  Masopust J, Andrýs C, Bažant J, Vyšata O, Kuca K, Vališ M. Masopust J, et al. Neuropsychiatr Dis Treat. 2015 Mar 6;11:619-23. doi: 10.2147/NDT.S80746. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 25834440 Free PMC article.

• Oral and Intranasal Ketamine Use in Treatment-Resistant Catatonia: A Clinical Case Report.

  Gregor EA, Zheng W. Gregor EA, et al. Am J Case Rep. 2023 Apr 25;24:e939530. doi: 10.12659/AJCR.939530. Am J Case Rep. 2023. PMID: 37095688 Free PMC article.

• Misdiagnosis of Catatonia.

  Mustafa FA, Nayar A. Mustafa FA, et al. Psychopharmacol Bull. 2020 Mar 12;50(1):48-50. Psychopharmacol Bull. 2020. PMID: 32214523 Free PMC article. No abstract available.

• Current electroconvulsive therapy practice and research in the geriatric population.

  Kerner N, Prudic J. Kerner N, et al. Neuropsychiatry (London). 2014 Feb;4(1):33-54. doi: 10.2217/npy.14.3. Neuropsychiatry (London). 2014. PMID: 24778709 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer